{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T01:02:31Z","timestamp":1775696551044,"version":"3.50.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology"],"published-print":{"date-parts":[[2012,9,11]]},"DOI":"10.1212\/wnl.0b013e3182698c64","type":"journal-article","created":{"date-parts":[[2012,8,30]],"date-time":"2012-08-30T04:52:33Z","timestamp":1346302353000},"page":"1130-1135","source":"Crossref","is-referenced-by-count":132,"title":["Disease-modifying drugs for multiple sclerosis in pregnancy"],"prefix":"10.1212","volume":"79","author":[{"given":"Ellen","family":"Lu","sequence":"first","affiliation":[{"name":"From the Department of Medicine (E.L., B.W.W., D.S., H.T.), Medical Genetics (C.G., D.S.), and Pediatrics (A.S.), Faculty of Medicine, University of British Columbia, Vancouver, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"From the Department of Medicine (E.L., B.W.W., D.S., H.T.), Medical Genetics (C.G., D.S.), and Pediatrics (A.S.), Faculty of Medicine, University of British Columbia, Vancouver, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"Guimond","sequence":"additional","affiliation":[{"name":"From the Department of Medicine (E.L., B.W.W., D.S., H.T.), Medical Genetics (C.G., D.S.), and Pediatrics (A.S.), Faculty of Medicine, University of British Columbia, Vancouver, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Synnes","sequence":"additional","affiliation":[{"name":"From the Department of Medicine (E.L., B.W.W., D.S., H.T.), Medical Genetics (C.G., D.S.), and Pediatrics (A.S.), Faculty of Medicine, University of British Columbia, Vancouver, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dessa","family":"Sadovnick","sequence":"additional","affiliation":[{"name":"From the Department of Medicine (E.L., B.W.W., D.S., H.T.), Medical Genetics (C.G., D.S.), and Pediatrics (A.S.), Faculty of Medicine, University of British Columbia, Vancouver, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Tremlett","sequence":"additional","affiliation":[{"name":"From the Department of Medicine (E.L., B.W.W., D.S., H.T.), Medical Genetics (C.G., D.S.), and Pediatrics (A.S.), Faculty of Medicine, University of British Columbia, Vancouver, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61620-7"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000127972"},{"key":"e_1_3_6_4_2","unstructured":"Martindale: The Complete Drug Reference 35th ed. London: Pharmaceutical Press; 2008."},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2007.00978.x"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.2307\/2991522"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509106543"},{"key":"e_1_3_6_8_2","unstructured":"Teva Pharmaceuticals. Copaxone (glatiramer acetate) [online]. Available at: www.copaxone.com\/pdf\/prescribinginformation.pdf. Accessed March 14 2010."},{"key":"e_1_3_6_9_2","unstructured":"US Food and Drug Administration. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling [online]. Available at: edocket.access.gpo.gov\/2008\/pdf\/E8-11806.pdf. Accessed March 14 2010."},{"key":"e_1_3_6_10_2","unstructured":"Biogen Idec. Avonex (interferon beta-1a) [online]. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/103628s5115lbl.pdf. Accessed March 14 2010."},{"key":"e_1_3_6_11_2","unstructured":"Bayer HealthCare. Betaseron (interferon beta-1b) [online]. Available at: berlex.bayerhealthcare.com\/html\/products\/pi\/Betaseron_PI.pdf. Accessed March 14 2010."},{"key":"e_1_3_6_12_2","unstructured":"Biogen Idec\/Elan Pharmaceuticals I. Tysabri (natalizumab) [online]. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/125104s015lbl.pdf. Accessed March 14 2010."},{"key":"e_1_3_6_13_2","unstructured":"Novartis Pharmaceuticals Corp. Gilenya (fingolimod) [online]. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022527s000lbl.pdf. Accessed March 14 2010."},{"key":"e_1_3_6_14_2","unstructured":"EMD Serono I\/C. Novantrone (mitoxantrone) [online]. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/019297s030s031lbl.pdf. Accessed March 14 2010."},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.966861"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2008.10.009"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000180575.77021.c4"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511401944"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181fd62bb"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509102366"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511422244"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-5376-z"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-0909-4"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458507077896"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-282X2009000400015"},{"key":"e_1_3_6_26_2","first-page":"969","article-title":"Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series","volume":"24","author":"Fragoso YD","year":"2010","unstructured":"Fragoso YD, Finkelsztejn A, Kaimen-Maciel DR, et al.. Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series. CNS Drugs 2010;24:969\u2013976.","journal-title":"CNS Drugs"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2010.11.016"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-010-5652-y"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000168905.97207.d0"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510394610"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03403781"},{"key":"e_1_3_6_32_2","unstructured":"Cunningham FG Leveno KJ Bloom SL Hauth JC Rouse DJ Spong CY. Fetal growth and development. In: Williams Obstetrics 23 ed. New York: McGraw-Hill; 2010."},{"key":"e_1_3_6_33_2","first-page":"S303","article-title":"Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis","volume":"17","author":"Giannini M","year":"2011","unstructured":"Giannini M, Portaccio E, Ghezzi A, et al.. Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis. Mult Scler 2011;17(suppl 10): S303. Abstract.","journal-title":"Mult Scler"},{"key":"e_1_3_6_34_2","first-page":"A273","article-title":"Multiple sclerosis and pregnancy experience from a nationwide database","volume":"76","author":"Hellwig K","year":"2011","unstructured":"Hellwig K, Haghikia A, Gold R.. Multiple sclerosis and pregnancy experience from a nationwide database. Neurology 2011;76(suppl 4):A273. Abstract.","journal-title":"Neurology"},{"key":"e_1_3_6_35_2","first-page":"S315","article-title":"Pregnancy outcomes from the Avonex\u00ae (interferon beta-1a) pregnancy exposure registry","volume":"16","author":"Foulds P","year":"2010","unstructured":"Foulds P, Richman S, Glick G, Onigman T, Hyde R.. Pregnancy outcomes from the Avonex\u00ae (interferon beta-1a) pregnancy exposure registry. Mult Scler 2010;16(suppl 10):S315. Abstract.","journal-title":"Mult Scler"},{"key":"e_1_3_6_36_2","first-page":"A554","article-title":"Use of glatiramer acetate during pregnancy: offering women a choice","volume":"74","author":"Miller AE","year":"2010","unstructured":"Miller AE, Reardon JL.. Use of glatiramer acetate during pregnancy: offering women a choice. Neurology 2010;74(suppl 2):A554. Abstract.","journal-title":"Neurology"},{"key":"e_1_3_6_37_2","first-page":"A457","article-title":"Preliminary evaluation of pregnancy outcomes from the Tysabri (natalizumab) pregnancy exposure registry","volume":"17","author":"Cristiano LM","year":"2011","unstructured":"Cristiano LM, Bozic C, Bloomgren G.. Preliminary evaluation of pregnancy outcomes from the Tysabri (natalizumab) pregnancy exposure registry. Mult Scler 2011;17(suppl 10):A457. Abstract.","journal-title":"Mult Scler"},{"key":"e_1_3_6_38_2","first-page":"A609","article-title":"Lack of interaction between fingolimod (FTY720) and oral contraceptives, and pregnancy experience in the clinical program of fingolimod in multiple sclerosis","volume":"76","author":"Collins W","year":"2011","unstructured":"Collins W, Francis G, Koren G, et al.. Lack of interaction between fingolimod (FTY720) and oral contraceptives, and pregnancy experience in the clinical program of fingolimod in multiple sclerosis. Neurology 2011;76(suppl 4):A609. Abstract.","journal-title":"Neurology"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.0b013e3182698c64","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T11:14:21Z","timestamp":1711538061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.0b013e3182698c64"}},"subtitle":["A systematic review"],"short-title":[],"issued":{"date-parts":[[2012,9,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,9,11]]}},"alternative-id":["10.1212\/WNL.0b013e3182698c64"],"URL":"https:\/\/doi.org\/10.1212\/wnl.0b013e3182698c64","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,11]]}}}